Irbesartan in patients with heart failure and preserved ejection fraction.
By B. Massie, P. Carson, J. McMurray, M. Komajda, R. McKelvie, M. Zile, S. Anderson, M. Donovan, E. Iverson, C. Staiger and 1 more. New England Journal of Medicine, 2008
1,881 citations recorded by the source corpus.
Subfields: Cardiology and Cardiovascular Medicine
View Paper: https://www.semanticscholar.org/paper/e9a61c8be630985fb3f836902ae4b2081350934e
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cardiology and Cardiovascular Medicine
- Barry A. Borlaug
- W. Paulus
- G. Fonarow
- T. Horwich
- James B. Strait
- E. Lakatta
- C. Herrmann-Lingen
- S. Laurent
Citations in the corpus
- Heart Failure With Preserved, Borderline, and Reduced Ejection Fraction: 5-Year Outcomes. (2017, result): “Previous studies have shown conflicting data with respect to survival in patients with HFpEF compared with HFrEF (4,5,7,9,11,17).”
- The 2015 Canadian Hypertension Education Program recommendations for blood pressure measurement, diagnosis, assessment of risk, prevention, and treatment of hypertension. (2013, result): “In one of these trials, Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) [560], the angiotensin receptor blocker irbesartan failed to lessen CV events compared with placebo.”
- ESC Guidelines for the diagnosis and treatment of acute and chronic heart failure 2012 (2012, background): “hospitalization (specifically, HF, myocardial infarction, unstable angina, arrhythmia, or stroke).(141)”
- Aging-associated cardiovascular changes and their relationship to heart failure (2012, background): “Their benefit in patients with preserved systolic function, however, is less certain.(87) There is an ongoing trial of spironolactone in patients with HF with preserved systolic function, but first outcomes are not expected before 2011.”
- 2007 Guidelines for the Management of Arterial Hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) (2007, result): “In one of these trials, Irbesartan in Heart Failure with Preserved Systolic Function (I-PRESERVE) [560], the angiotensin receptor blocker irbesartan failed to lessen CV events compared with placebo.”